Cell Therapy Markets

Table of Contents

1. Overview

• 1.1 Statement of Report
• 1.2 About this Report
• 1.3 Scope of the Report
• 1.4 Objectives
• 1.5 Methodology
• 1.6 Executive Summary

2. Overview of the Science of Cell Therapy

• 2.1 Cell Therapy Technologies
  • 2.1.1 Stem Cell Therapies
  • 2.1.2 Umbilical Cord Blood Stem Cell Transplant
  • 2.1.3. Cord Blood Collection, Transfusion and Storage Market
  • 2.1.4 Cell Therapy and Related Technologies
• 2.2 Organ Transplantation to Cell Therapy
• 2.3 Sources of Cells for Therapy
• 2.4 Types of Cells Available for Therapy
  • 2.4.1 Cells and Protein/Gene Therapy
  • 2.4.2 Cell Therapy and Regenerative Medicine
  • 2.4.3 Cells Therapy and Tissue Engineering
• 2.5 Cell Therapy Compared to Small Molecule Drugs, Biologics and Tissue Engineered Products
• 2.6 What Conditions are Amenable to Cell Therapy and Why?
  • 2.6.1 Wounds and Burns
  • 2.6.2 Aesthetic Medicine: Botox and Collagen
  • 2.6.3 Cell Therapy for Bones and Joints
  • 2.6.4 Blood Component Therapy
  • 2.6.5 Immunotherapy for Cancer
  • 2.6.6 Cardiovascular Disorders
  • 2.6.7 Diabetes Mellitus
  • 2.6.8 Neurological Disorders
  • 2.6.9 Urinary Incontinence
  • 2.6.10 Cells for Drug Discovery
• 2.7 Properties of Stem Cells and Their Classification
• 2.8 Stem Cell Differentiation
• 2.9 Stem Cell Therapy
• 2.10 Market Opportunity in the Stem Cell Marketplace
• 2.11 Potential Stem Cell Commercial Applications
  • 2.11.1 Cord Blood Stem Cells and Cord Blood Stem Cell Banking: Current Market Environment and Opportunity
  • 2.11.2 Qualitative and Quantitative Trends in the Stem Cells Space
  • 2.11.3 Utilization of the Different Classes of Stem Cells
  • 2.11.4 Quantitative Metrics of the Stem Cell Research Marketplace: Number of Experiments Performed, Research Spending Trends and Growth

3. The Cell Therapy Market

• 3.1 Market Overview
• 3.2 The Overall Cell Therapy Market Opportunity
• 3.3 Stem Cell Therapies
  • 3.3.1 Cell Therapy/Regenerative Therapy Markets
  • 3.3.2 Market Size According to Geographical Areas
• 3.4 Competitive Landscape of the Stem Cells Marketplace
  • 3.4.1 Evolution of Research Activities with the Different Types of Stem Cells: Current Usage Trends and Usage in 12 to 18 Months
  • 3.4.2 Types of Research Activities the End-User Community Performing with the Different Types of Stem Cells
  • 3.4.3 Challenges Facing Stem Cell Researchers
  • 3.4.4 Market Drivers
  • 3.4.5 Research Questions Being Addressed in the Stem Cells Space
  • 3.4.6 Focus on Cancer Stem Cells
  • 3.4.7 Summary of Challenges and Opportunities in the Stem Cells Space Based on TriMark' s Analysis
  • 3.4.8 Unmet Product Needs in the Stem Cells Research Space and Licensing/IP Constraints
• 3.5 Competitive Landscape
  • 3.5 1 Cell Therapy Market
  • 3.5.2 Stem Cells Marketplace
• 3.6 Market Shares of Companies Offering Different Stem Cells
• 3.7 SWOT Analysis of the Major Stem Cell Market Segments
• 3.8 Market Size and Forecasts
  • 3.8.1 The Research Market
  • 3.8.2 Cell Therapy/Regenerative Therapy Markets

4. The Technology of Cell Therapy

• 4.1 Growing Cells-An Overview from Source to Product
• 4.2 Cell Culture
  • 4.2.1 Cell Culture Process
  • 4.2.2 Cell Culture Applications
  • 4.2.3 Types of Mammalian Cultures
  • 4.2.4 Plant Cell Culture
  • 4.2.5 Commercialization of Cell Culture Products
  • 4.2.6 Companies in Cell Culture Technology
• 4.3 Cell Lines
• 4.4 Large Scale Manufacturing
• 4.5 Making Product, Shipping, Distribution and Storage
• 4.6 Quality Control and Safety
• 4.7 Delivery Systems for Cell Therapy
• 4.8 Basic Technologies for Cell Therapy
  • 4.8.1 Flow Cytometry and Cell Sorting
• 4.9 Cell Seperation Techniques
  • 4.9.1 Density-Based Isolation Methods
    • 4.9.1.1 Ficoll-hypaque-based Density Gradient System NIM2
    • 4.9.1.2 Lymphocyte Separation Medium
    • 4.9.1.3 Density Gradient Media
  • 4.9.2 Micro Sieves
  • 4.9.3 Antibody-based Cell Separation Techniques
  • 4.9.4 Magnet Sorting
  • 4.9.5 Automated Seperation Procedures
  • 4.9.6 Aldesorter System for Isolation of Stem Cells
• 4.10 Cell Preservation Technology
• 4.11 Selective Expansion of T Cells for Immunotherapy
• 4.12 Devices for Delivery of Cell Therapy
  • 4.12.1 Artificial Cells
  • 4.12.2 Cell Encapsulation
    • 4.12.2.1 Range of Therapeutic Tretaments
    • 4.12.2.2 Technical Barriers
    • 4.12.2.3 Current Challenges
  • 4.12.3 Therapeutic Applications of Encapsulated Cells
    • 4.12.3.1 Cancer Therapy
    • 4.12.3.2 Therapeutic Genes
    • 4.12.3.3 Retinal Disease
  • 4.12.4 Use of Microencapsulated Genetically Modified Cells
  • 4.12.5 Nanoparticle-Aptamer Bioconjugates

5. Stem Cells

• 5.1 Basic Properties of Stem Cells and Their Classification
  • 5.1.1 Embryonic Stem Cells
  • 5.1.2 Embryonic Germ Cells
• 5.2 Sources of Stem Cells
• 5.3 Challenges Facing Stem Cell Researchers
• 5.4 Stem Cells for Drug Toxicity Screening
• 5.5 Market Analysis of the Stem Cells Space

6. Clinical Applications of Cell Therapy

• 6.1 Cell Therapy for Hematological Disorders
  • 6.1.1 Hematopoietic Cells for Hematologic Diseases and to Prevent Immune Rejection
  • 6.1.2 Hematopoietic Cytokines
  • 6.1.3 Prochymal™ for the Treatment of Acute Graft versus Host Disease
  • 6.1.4 Cell/Gene Therapy of Hemophilia B
  • 6.1.5 Ex Vivo Cell/Gene Therapy of Hemophilia A
  • 6.1.6 Therapies for the Hemophilia Market
  • 6.1.7 Stem Cell Transplant for Sickle Cell Anemia
  • 6.1.8 Modified Hematopoietic Stem Cells for Chronic Acquired Anemias
  • 6.1.9 Stem Cell Therapy of Hemoglobinopathies
  • 6.1.10 Future Prospects of Cell Therapy of Hematological Disorders
• 6.2 Cell Therapy for Immunological Disorders
  • 6.2.1 Treatment of Crohn' s Disease with Stem Cells
• 6.3 Cell therapy for Diabetes Mellitus
  • 6.3.1 Islet Cells for Diabetes
• 6.4 Cell Therapy for Liver Disorders
  • 6.4.1 About Liver Disease
  • 6.4.2 Technology Summary
• 6.5 Cell Therapy for Renal Disorders
  • 6.5.1 Human Renal Epithelial Cells Administered Ex Vivo
• 6.6 Cell Therapy for Disorders of Bones and Joints
  • 6.6.1 Osteoblasts for Osteoporosis and Non-Union Bone Fractures
  • 6.6.2 Chondrocytes for Osteoarthritis and the Use of hESCs
  • 6.6.3 Knee Injury Treatment for Meniscectomy Patients Using Mesenchymal Stem Cells
• 6.7 Wound Healing: Skin and Soft Tissue Repair
  • 6.7.1 Autologous Living Cell Therapy
  • 6.7.2 Cell Therapy for Corneal Repair
    • 6.7.2.1 Current Clinical Status for Cornea Disease and Transplant
    • 6.7.2.2 Regenerative Cornea Product from Cellseed
• 6.8 Role of Cells in Tissue Engineering and Reconstructive Surgery
• 6.9 Cell Therapy for Cardiovascular Disorders
  • 6.9.1 Introduction to Cardiovascular Disorders
    • 6.9.1.1 Myocardial Infarction (Heart Attack)
    • 6.9.1.2 Congestive Heart Failure (CHF)
    • 6.9.1.3 Heart Failure Classification
    • 6.9.1.4 Diagnosis and Management of Heart Failure
    • 6.9.1.5 Drug Therapies
    • 6.9.1.6 Bi-ventricular Pacers
    • 6.9.1.7 Heart Transplantation and Other Surgical Procedures
    • 6.9.1.8 Ventricular Assist Devices
    • 6.9.1.9 Market Potential
    • 6.9.1.10 Limitations of Current Therapies for Myocardial Ischemic Disease
  • 6.9.2 Sector Overview of Cell Based Cardiac Repair
    • 6.9.2.1 Categories of Cell Types for Cell Therapy
      • 6.9.2.1.1 Autologous Skeletal Myoblasts
      • 6.9.2.1.2 Cardiocytes
      • 6.9.2.1.3 Mesenchymal Stem Cell (MSC)
      • 6.9.2.1.4 Bone Marrow Derived Stem Cells
      • 6.9.2.1.5 Fetal Cardiomyocytes
      • 6.9.2.1.6 Smooth Muscle Cells
      • 6.9.2.1.7 Immortalized Myoblasts
      • 6.9.2.1.8 Syngeneic Skeletal Myoblasts
      • 6.9.2.1.9 Fibroblasts
      • 6.9.2.1.10 Embryonic Stem Cell
      • 6.9.2.1.11 Bone Marrow Derived Stromal Cells
    • 6.9.2.2 Current Cell Therapies for Myocardial Ischemic Disease
      • 6.9.2.2.1 Cardiomyocytes for Heart Disease
      • 6.9.2.2.2 Mesenchymal Stem Cells (MSCs) Provacel™, (Osiris Therapeutics)
      • 6.9.2.2.3 Living Regenerative Cardiac Patch (Cellseed)
      • 6.9.2.2.4 Bioheart' s MyoCell
      • 6.9.2.2.5 Viacell' s Unrestricted Somatic Stem Cells (USSCs)
      • 6.9.2.2.6 Mytogen' s Autologous Myoblasts
  • 6.9.3 Research Methods for Delivery of Cells to the Heart
    • 6.9.3.1 Cell Transplantation for Cardiac Repair
    • 6.9.3.2 Using Nanofibers to Deliver Insulin Growth Factor
  • 6.9.4 Role of Stem Cells in Repair of the Heart
    • 6.9.4.1 Cardiac Autologous Stem Cells
      • 6.9.4.1.1 Expansion of Stem Cells
      • 6.9.4.1.2 Role of ESCs in Repair of the Heart
      • 6.9.4.1.3 Transplantation of BMPCs
      • 6.9.4.1.4 Transplantation of CMPCs
      • 6.9.4.1.5 Transplantation of hESCs
      • 6.9.4.1.6 Transplantation of Skeletal Myoblasts
      • 6.9.4.1.7 Transplantation of Autologous Angiogenic Cell Precursors
      • 6.9.4.1.8 Regeneration of Chronic Myocardial Infarcts by HSC Therapy
      • 6.9.4.1.9 Transplantation of Adipose-Derived Stem Cells
      • 6.9.4.1.10 Intracoronary Infusion of Bone Marrow-Derived Cells for AMI
      • 6.9.4.1.11 Human Mesenchymal Stem Cells for Cardiac Regeneration
      • 6.9.4.1.12 Simultaneous Transplantation of Autologous MSCs and Skeletal Myoblasts
  • 6.9.5 Role of Genetically Modified Cells
    • 6.9.5.1 Gene Therapy Using Modified Stem Cells
    • 6.9.5.2 Use of Cells Secreting Vascular Endothelial Growth Factor
  • 6.9.6 Cell Therapy for Congestive Heart Failure
    • 6.9.6.1 Angiocell Gene Therapy for Congestive Heart Failure
  • 6.9.7 Role of Cell Therapy in Cardiac Arrhythmias
    • 6.9.7.1 Genetically Modified Cell Grafts
    • 6.9.7.2 Cardiomyocyte Cell Grafts
    • 6.9.7.3 Antiarrhythmic Potential of Cell Therapy Strategies
    • 6.9.7.4 Vectors for Gene Therapy
    • 6.9.7.5 Methods of Gene Delivery
    • 6.9.7.6 Gene Therapy in Cardiac Arrhythmias
    • 6.9.7.7 Current Problems with Gene Therapy
  • 6.9.8 Cell Therapy for Cardiac Tissue Engineering of Blood Vessels with Cells
    • 6.9.8.1 Fetal Cardiomyocytes Seeding in Tissue-Engineered Cardiac Grafts
  • 6.9.9 Competitive Landscape for Cell Therapy Based Cardiovascular Products
  • 6.9.10 Evaluation of Cell Therapy as Therapy for Heart Disease
• 6.10 Cell Therapy for Cancer
  • 6.10.1 Introduction
  • 6.10.2 Cell Therapy Technologies for Cancer
  • 6.10.3 Cellular Immunotherapy for Cancer Treatments for Cancer by ExVivo Mobilization of Immune Cells
  • 6.10.4 Alternative Cancer Treatment Market
  • 6.10.5 Autologous Tumor Cell Vaccines and Dendritic Cell Therapy
  • 6.10.6 The Use of Dendritic Cells for Cancer Vaccination
    • 6.10.6.1 Collection of Cells
    • 6.10.6.2 Basics of Dendritic Cell Vaccines
    • 6.10.6.3 Dendritic Cells Treated with Purified Tumor Antigen
    • 6.10.6.4 Stimulation of Immature Dendritic Cells to Become Mature Dendritic Cells
    • 6.10.6.5 Cell Fragments of Dendritic Cells Primed with Tumor Cell Antigens
  • 6.10.7 Gene Therapy
  • 6.10.8 Stem Cell-Based Anticancer Therapies
  • 6.10.9 Other Cell Therapy Vaccines
  • 6.10.10 Stem Cell Transplantation in Cancer
    • 6.10.10.1 Peripheral Blood Stem Cell Transplantation
    • 6.10.10.2 Autologous Stem Cell Transplantation
    • 6.10.10.3 Complications of Stem Cell Transplants in Cancer
    • 6.10.10.4 Mesenchymal Stem Cell Transplantation in Cancer
    • 6.10.10.5 Umbilical Cord Blood Transplant for Leukemia
    • 6.10.10.6 Hesc-Derived NK Cells for Treatment of Cancer
  • 6.10.11 Innovations in Cell-Based Therapy of Cancer
    • 6.10.11.1 Cancer Therapy Based on NK-92 Cells
    • 6.10.11.2 Myoblast Mediated Gene Therapy
  • 6.10.12 Cancer Stem Cells
  • 6.10.13 Mesenchymal Stem Cells for the Treatment of Gliomas
  • 6.10.14 Companies Involved in Cell-Based Cancer Therapy
  • 6.10.15 Stem Cell-Based Anti-Cancer Therapies
• 6.11 Cell Therapy for Neurological Disorders
  • 6.11.1 Oligodendrocytes for Spinal Cord Injury and Dopaminergic Neurons for Parkinson' s Disease
  • 6.11.2 Neural Stem Cells as a Treatment for Neuronal Ceroid Lipofuscinosis
  • 6.11.3 Epilepsy and Neuropathic Pain Markets
  • 6.11.4 Delivery of Naturally Occurring Neurotrophic Factors
  • 6.11.5 Repairing the Nervous System
  • 6.11.6 Genes Permanently Incorporated into Targeted Cells
  • 6.11.7 Neurological Disorders Responding to Neurotrophic Factors
  • 6.11.8 Ceregene' s Products
  • 6.11.9 Parkinson' s Disease
    • 6.11.9.1 Introduction
    • 6.11.9.2 Market Opportunity
    • 6.11.9.3 Stem Cell Line for Functional Dopaminergic Neurons
• 6.12 Cell Therapy for Stroke
  • 6.12.1 Introduction
  • 6.12.2 Market Opportunity
  • 6.12.3 Stem Cell Therapy for Chronic Stroke Disability
• 6.13 Cell Therapy for Dental Treatments
• 6.14 Gene Therapy
  • 6.14.1 Vehicles for Gene Transfer
  • 6.14.2 Viral Vectors for Gene Therapy
  • 6.14.3 Nonviral Vectors: Liposomes
  • 6.14.4 Gene Therapy for Hematopoietic Derived Diseases
• 6.15 hESC-Derived Hepatocytes for Drug Screening and Toxicology

7. Ethics, Regulation and Funding

• 7.1 Ethics
• 7.2 The U.S. Position on hESC Research
• 7.3 Regulation and Legislation
  • 7.3.1 Regulations on Stem Cell Research
  • 7.3.2 Regulation of Tissue Engineered Products
• 7.4 Investment
• 7.5 Interdisciplinary and Public-Private Partnerships
• 7.6 Corporate Partnerships
  • 7.6.1 ReNeuron and CellSeed Collaboration Using ReNcellTM Liver Cell Lines
  • 7.6.2 Plureon Corporation in Agreement with BD
  • 7.6.3 Icoria Inc. Research Agreement with Vesta Therapeutics
• 7.7 Corporate Mergers
  • 7.7.1 GenVec' s Acquisition of Diacrin, Inc.
  • 7.7.2 Genvec Transferred its Cell Transplantation Assets to Mytogen, Inc.
• 7.8 European Regulation on Advanced Cell Therapies
• 7.9 Processing Autologous Cell Products-Discussing the Regulatory and Commercial Impact of Patient-Specific Therapies
• 7.10 Stem Cell Research Funding

8. Future Directions in Cell Therapy

• 8.1 Cell Therapy Future Markets According to Therapeutic Area
  • 8.1.1 Brain and Central Nervous System Applications
  • 8.1.2 Cardiology Applications
  • 8.1.3 Diabetes Applications
  • 8.1.4 Tissues and Organs
  • 8.1.5 Other Applications
• 8.2 Unmet Market Needs in Cell Therapy
• 8.3 Future Prospects of Cell Therapy
  • 8.3.1 Autologous Stem Cells
  • 8.3.2 Pluripotential Stem Cells Lines
  • 8.3.3 Angiogenesis
  • 8.3.4 Reprogramming Stem Cells
• 8.4 Clinical Trials in Cell Therapy
• 8.5 Analytical Tools for Cell Therapy
• 8.6 Ethical Concerns of Cloning for Reproductive Purposes
  • 8.6.1 Ethical Concerns
  • 8.6.2 Policy and Regulation
• 8.7 Cloning for the Isolation of Human ES Cells
  • 8.7.1 Ethical Concerns
  • 8.7.2 Policy and Regulation
• 8.8 Somatic Cell Nuclear Transfer Generating Pluripotential Stem Cells
• 8.9 Funding of Stem Cell Research from Non-Federal Sources
• 8.10 Industry Challenges for Cell Therapy Manufacturing
  • 8.10.1 Cost Challenges to Manufacturing Processes
  • 8.10.2 Supply Challenges for Current Manufacturing Processes
• 8.11 Future Prospects of Cell Therapy
• 8.12 Challenges for Cell Therapy
• 8.13 Therapeutic Cloning
• 8.14 Future Market Potential of Adult Versus Embryonic Stem Cells
• 8.15 Challenges of Developing a Cell Therapy Product Compared to a Conventional Drug Product
• 8.16 Transition from a Techology Driven Company to a Product Driven Company
• 8.17 Exploiting Technology Platforms for Commercial Success
• 8.18 At What Point Do You Seek a Partner in Cell Therapy Development
• 8.19 Cell and Tissue Therapies Product Development and Manufacture
  • 8.19.1 What Commercialization Models are Emerging to Cope with Complex Manufacturing Required by Cell Therapies?
  • 8.19.2 Optimizing Product Development, Manufacture and Commercialization of Autologous and Allogeneic Cell Therapies

9. Company Profiles

• 9.1 Aastrom Biosciences
• 9.2 Advanced Cell Technology
• 9.3 Advanced Cell Therapeutics
• 9.4 Aldagen
• 9.5 AllCells, LLC.
• 9.6 AmCyte
• 9.7 Arthro Kinetics
• 9.8 AstraZeneca
• 9.9 Australian Stem Cell Centre
• 9.10 Axordia
• 9.11 BioE
• 9.12 Bioheart
• 9.13 BioTransplant Incorporated
• 9.14 BrainStorm Cell Therapeutics
• 9.15 Cambrex
• 9.16 Cardio3
• 9.17 Cartela
• 9.18 Cellartis
• 9.19 Cellerant Therapeutics
• 9.20 CellSeed Inc.
• 9.21 Cellular Dynamics International
• 9.22 Ceregene, Inc.
• 9.23 Cryo-Cell International
• 9.24 Cytori Therapeutics
• 9.25 ES Cell International
• 9.26 Fraunhofer Institute for Cell Therapy and Immunology
• 9.27 Gamida Cell Therapeutics
• 9.28 GE Healthcare
• 9.29 GenVec, Inc.
• 9.30 Geron
• 9.31 GlaxoSmithKline
• 9.32 Intercytex
• 9.33 Invitrogen
• 9.34 Institute for Stem Cell Research, University of Edinburgh
• 9.35 Isolagen
• 9.36 Lexicon Genetics
• 9.37 Lund Stem Cell Center, Lund University
• 9.38 MaxCyte
• 9.39 Miltenyi Biotec
• 9.40 NeuroNova
• 9.41 Norwegian Center for Stem Cell Research
• 9.42 NovaThera
• 9.43 NsGene
• 9.44 Osiris Therapeutics
• 9.45 Pfizer
• 9.46 Plureon
• 9.47 Pluristem Life Systems
• 9.48 Progenitor Cell Therapy, LLC
• 9.49 Regenerative Medicine Network (RegMedNet), University of Leipzig
• 9.50 RenaMed Biologics
• 9.51 ReNeuron
• 9.52 StemCells, Inc.
• 9.53 Stem Cell Innovations
• 9.54 Stem Cell Sciences
• 9.55 StemCell Technologies
• 9.56 Thermogenesis
• 9.57 TiGenix
• 9.58 Tissue Engineering and Regenerative Medicine Centre, Imperial College London
• 9.59 UK Stem Cell Bank
• 9.60 UK Stem Cell Foundation
• 9.61 ViaCell
• 9.62 Vesta Therapeutics, Inc.
• 9.63 VistaGen Therapeutics
• 9.64 Wolfson Centre for Age-Related Diseases, King' s College, London
• 9.65 AlphaCord
• 9.66 Celgene
• 9.67 Cord Blood Registry
• 9.68 Angiogene
• 9.69 EntreMed

Appendix

• Sources of Umbilical Cord Blood for Stem Cell Research
• National Marrow Donor Program
• For Profit Storage of Cord Blood
• Stem Cells from Frozen Embryos
• Stem Cell Policy Statement
• Glossary of Terms in Cell Biology

LIST OF TABLES

• Table 2.1: U.S. Companies Involved in Cord Blood Banking
• Table 2.2: U.K. Companies Involved in Cord Blood Banking
• Table 2.3: Waiting List for Organ Transplants in U.S.
• Table 2.4: Number of Organ Transplants Carried out in U.S., January-March 2006
• Table 2.5: Sources of Cells for Therapy and Other Applications
• Table 2.6: U.S. Wound Care Market, 2003-2012
• Table 2.7: Stem Cell Therapeutics for Orthopedic Disease in Development
• Table 2.8: Cellular Therapies in Orthopedics Trauma and Fracture Markets
• Table 2.9: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development
• Table 2.10: Stem Cell-Based Therapeutics for Vascular Diseases in Development
• Table 2.11: Stem Cell Therapeutics for Type I Diabetes in Development
• Table 2.12: Stem Cell Therapeutics for Neurological Disease in Development
• Table 2.13: Key Properties of Stem Cells
• Table 2.14: Sources of Human Stem Cells
• Table 2.15: The Different Types of Stem Cells and their Properties
• Table 2.16: Adult Stem Cell (ASC) Differentiation Properties
• Table 2.17: Characteristics of Different Stem Cell Types and Associated Market Opportunities
• Table 2.18: Segmentation of the Stem Cell Market by Type/Lineage of Stem Cell
• Table 2.19: Selected Cord Blood Banks in the U.S.
• Table 2.20: Selected Companies in the Cord Blood Stem Cell Technology and Therapeutics Development Space
• Table 3.1: Worldwide Cell Therapy Markets, 2005-2012
• Table 3.2: Worldwide Stem Cell, Cytokine, and Growth Factor Cell Therapy Markets, 2005-2012
• Table 3.3: The World Market for Stem Cell Products and Services, 2005-2012
• Table 3.4: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
• Table 3.5: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
• Table 3.6 Publicly-Held Stem Cell Companies
• Table 3.7: Market Shares of Companies/Institutions Offering Different Stem Cells to Researchers
• Table 3.8: Market Shares of Companies/Institutions Offering Reagents for Stem Cell Research
• Table 3.9: Privately-Held Stem Cell Companies
• Table 3.10: Product and Custom Service Providers in the Stem Cells Space
• Table 3.11: Cord Blood Stem Cell Companies
• Table 3.12: Adult Stem Cell Companies
• Table 3.13: Reagents, Media and Consumable Companies
• Table 3.14: Stem Cells Research Market Forecast, 2006-2011
• Table 4.1: Worldwide Market for Flow Cytometry Instruments and Reagents, 2000-2010
• Table 4.2: Leading Players in Flow Cytometry Instrumentation
• Table 5.1: Leading Stem Cell Companies
• Table 6.1: Hematopoietic Cytokines
• Table 6.2: Skin Rejuvination (Aesthetics) Markets, 2005-2012
• Table 6.3: Burn Scars Markets, 2005-2012
• Table 6.4: Acne Scars, 2005-2012
• Table 6.5: NYHA Classifications for Stages of Heart Failure
• Table 6.6: Worldwide Market for Cardiac Care Therapeutics, 1999-2010
• Table 6.7: Examples of Cell Types Used in Cardiac Repair
• Table 6.8: Clinical Trials of MyoCell
• Table 6.9: The Common Metrics Used to Evaluate the Efficacy of These Therapies Include
• Table 6.10: Stemline™ Platform Media for Expansion and Maturation of Stem Cells
• Table 6.11: Gene Transfer Vehicles
• Table 7.1: Investment in Stem Cell Research in Different Countries
• Table 7.2: International Location of hESC Lines
• Table 7.3: Unpublished Lines (Not Peer-Reviewed)
• Table 8.1: Delivery of Cells for Heart Repair Technologies

LIST OF FIGURES

• Figure 2.1: Release of Leukocytes into the Bloodstream
• Figure 2.2: Derivation of Embryonic Stem Cells (ESCs) from the Inner Cell Mass of Blastocysts
• Figure 2.3: Classification of Stem Cells: Embryonic Stem Cells versus Adult Stem Cells
• Figure 2.4: Somatic Cell Nuclear Transfer (SCNT)
• Figure 2.5: Segmentation of the Stem Cells Marketplace Based upon Commercial Offerings-Products and Services
• Figure 2.6: Geographical Breakout of Stem Cell End-user Survey Respondents
• Figure 2.7: Affiliation (Pharma, Biotech, Academic/University) of Stem Cell End-user Survey Respondents
• Figure 2.8: Most of the Survey Respondents are Studying Stem Cells or Using Stem Cells in Their Research
• Figure 2.9: Length of Time Survey Respondent Pool Studying Stem Cells or Using Stem Cells in Their Research Activities
• Figure 2.10: Utilization/Research with Different Stem Cell Types
• Figure 2.11: Range of Number of Experiments Involving Stem Cells Conducted per Week
• Figure 2.12: Do the two Sub-Populations of Researchers Occupying the Two Ends of the Throughput Scale Exhibit Differences with Respect to Usage of Different Stem Cell Types?
• Figure 2.13: How Much Research Dollars Are Spent Monthly on Research/Studies with Different Stem Cell Types
• Figure 2.14: Growth of Research Spending in Various Segments of the Stem Cells Space (Defined by Stem Cell Type)
• Figure 3.1: Global Forecast of Revenues for Stem Cell and Cytokine Therapies in Regenerative Medicine, 2003-2010
• Figure 3.2: Stem Cell Research Market, 2006-2011
• Figure 3.3: Growth in End-User Utilization of the Various Different Stem Cell Types
• Figure 3.4: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
• Figure 3.5: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
• Figure 3.6: Broad Classification of Research Activities Being Performed with Stem Cells by Researchers
• Figure 3.7: Current End-User Utilization Category of Adult Stem Cells (ASCs)
• Figure 3.8: Current End-User Utilization Category of Human Embryonic Stem Cells (hESCs)
• Figure 3.9: Current End-User Utilization Category of Human Cord Blood Stem Cells
• Figure 3.10: Current End-User Utilization Category of Animal Stem Cells
• Figure 3.11: Current End-User Utilization Category of Cancer Stem Cells
• Figure 3.12: Challenges in the Study or Utilization of Adult Stem Cells (ASCs)
• Figure 3.13: Challenges in the Study or Utilization of Human Embryonic Stem Cells (hESCs)
• Figure 3.14: Challenges in the Study or Utilization of Human Cord Blood Stem Cells
• Figure 3.15: Challenges in the Study or Utilization of Animal Stem Cells
• Figure 3.16: Challenges in the Study or Utilization of Cancer Stem Cells
• Figure 3.17: Top Unmet Needs in Commercial Products in the Stem Cells Research Space
• Figure 3.18: Stem Cells Research Market, 2006-2011
• Figure 4.1: Cell Microencapsulation: Promise and Progress
• Figure 6.2: Ceregene Pipeline of Products
• Figure 7.1: FDA Review Centers
• Figure 7.2: World Map of Stem Cell Regulations